The Health Effects of Mandatory Prescriptions
Author
Abstract
Suggested Citation
DOI: 10.1086/467136
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- F.M. Scherer, 2007. "Uncertainty and choice: the challenges of pharmaceutical efficacy, safety, and cost," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 267-283.
- Peter T. Leeson & Henry A. Thompson, 2023. "Public choice and public health," Public Choice, Springer, vol. 195(1), pages 5-41, April.
- Walter E. Block, 2017. "Radical Privatization: Oceans, Roads,Heavenly Bodies," Romanian Economic Business Review, Romanian-American University, vol. 12(2), pages 41-56, June.
- Higgins, Matthew J. & Yan, Xin & Chatterjee, Chirantan, 2021.
"Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling,"
Research Policy, Elsevier, vol. 50(1).
- Matthew J. Higgins & Xin Yan & Chirantan Chatterjee, 2018. "Unpacking the effects of adverse regulatory events: Evidence from pharmaceutical relabeling," NBER Working Papers 24957, National Bureau of Economic Research, Inc.
- Olson, Mary K., 2008. "The risk we bear: The effects of review speed and industry user fees on new drug safety," Journal of Health Economics, Elsevier, vol. 27(2), pages 175-200, March.
- Khwaja, Ahmed & Sloan, Frank & Salm, Martin, 2006. "Evidence on preferences and subjective beliefs of risk takers: The case of smokers," International Journal of Industrial Organization, Elsevier, vol. 24(4), pages 667-682, July.
- Theodore E. Keeler & Teh‐wei Hu & Alison Keith & Richard Manning & Martin D. Marciniak & Michael Ong & Hai‐Yen Sung, 2002. "The benefits of switching smoking cessation drugs to over‐the‐counter status," Health Economics, John Wiley & Sons, Ltd., vol. 11(5), pages 389-402, July.
- David Barker, 2008. "Ethics and Lobbying: The Case of Real Estate Brokerage," Journal of Business Ethics, Springer, vol. 80(1), pages 23-35, June.
- Mary K. Olson, 2002. "Pharmaceutical Policy Change and the Safety of New Drugs," Journal of Law and Economics, University of Chicago Press, vol. 45(S2), pages 615-642.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ucp:jlawec:v:30:y:1987:i:2:p:207-38. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Journals Division (email available below). General contact details of provider: https://www.journals.uchicago.edu/JLE .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.